IPO Listed
Avalyn Pharma IPO
US$300m raised
Lodged 29 Apr 2026 · NASDAQ: AVLN
Advisers
Lead managers
- Bookrunner
- Legal adviser
- Issuer
- Avalyn Pharma
- Issuer based in
- United States
- Listed
- 30 Apr 2026
- Sector
- Biotech
- Tags
- Biotech, Pharma, Rare Disease
In the league tables
Similar deals
- Quince Therapeutics placement May 2026 · US$115m · Biotech
- Hemab Therapeutics Holdings IPO Apr 2026 · US$302m · Biotech
- Mentari Therapeutics placement May 2026 · US$290m · Biotech
- Veradermics IPO Feb 2026 · US$256m · Dermatology
- Seaport Therapeutics IPO Apr 2026 · US$255m · Biotech
Sources
- Apr 2026 Guggenheim Securities: Joint Bookrunner to Avalyn Pharma on its Initial Public Offering guggenheimsecurities.com
- 30 Apr 2026 Final IPO prospectus (424B4), Avalyn Pharma Inc. sec.gov
- 30 Apr 2026 Avalyn Pharma $300 million IPO davispolk.com
- 4 May 2026 Goodwin Guides Avalyn on Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for a Total of $345 Million goodwinlaw.com




